Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15019791 | 0.88 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1POLBHPGDTP53 | |
| SCHEMBL2043767 | 0.86 | TP53 (0.55) | ALDH1A1NPC1HPGDTP53ALOX12 | |
| SCHEMBL1996494 | 0.82 | GRM5 (0.43) | ALDH1A1TP53GAAADORA2AMAPT | |
| SCHEMBL4189968 | 0.82 | MEN1 (0.48) | ALDH1A1TP53GAAADORA2AMAPT | |
| SCHEMBL25170232 | 0.81 | NPC1 (0.48) | ALDH1A1NPC1TP53ALOX12ADORA2A | |
| SCHEMBL29254943 | 0.80 | CA12 (0.49) | SMN1; SMN2ALDH1A1NPC1HPGDTP53 | |
| SCHEMBL2926405 | 0.80 | HSD17B10 (0.51) | SMN1; SMN2ALDH1A1NPC1POLBHPGD | |
| SCHEMBL8046082 | 0.78 | GAA (0.42) | SMN1; SMN2ALDH1A1NPC1TP53GAA | |
| SCHEMBL22768993 | 0.78 | PDE4D (0.53) | SMN1; SMN2ALDH1A1NPC1POLBHPGD | |
| SCHEMBL12442229 | 0.78 | NPC1 (0.52) | SMN1; SMN2ALDH1A1NPC1POLBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231647-A1 | TETRAZOLE DERIVATES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20090131454-A1 | New compounds 067 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | claimed |
| WO-2009054785-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | claimed |
| US-20110306768-A1 | PROCESSES FOR THE MANUFACTURE OF 3--PYRIDINE, 4-METHYL-3-METHYLTHIO-5-(3-PYRIDYL)-L,2,4-TRIAZOLE, AND (1R)-1-[2-(3-METHYLPHENYL)-2H-TETRAZOL-5-YL]ETHANOL | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306768-A1 | PROCESSES FOR THE MANUFACTURE OF 3--PYRIDINE, 4-METHYL-3-METHYLTHIO-5-(3-PYRIDYL)-L,2,4-TRIAZOLE, AND (1R)-1-[2-(3-METHYLPHENYL)-2H-TETRAZOL-5-YL]ETHANOL | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306768-A1 | PROCESSES FOR THE MANUFACTURE OF 3--PYRIDINE, 4-METHYL-3-METHYLTHIO-5-(3-PYRIDYL)-L,2,4-TRIAZOLE, AND (1R)-1-[2-(3-METHYLPHENYL)-2H-TETRAZOL-5-YL]ETHANOL | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2379531-A1 | PROCESSES FOR THE MANUFACTURE OF 3-{4-METHYL-5- [ (IR) -1- (2- (3-METHYLPHENYL) -2H-TETRAZOL-5-YL) -ETHOXY]-4H- [1,2, 4]TRIAZOL-3-YL} -PYRIDINE, 4-METHYL-3-METHYLTHIO-5- (3- PYRIDYL)-L,2,4-TRIAZOLE, AND (IR) -1- [2- (3-METHYLPHENYL) -2H- TETRAZOL-5-YL]ETHANOL | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-7960422-B2 | Pharmaceutically active compounds containing tetrazolyl and triazolyl rings | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009054785-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009054785-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009051556-A1 | TETRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | disclosed |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111857-A1 | 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5 | GRM5, GRIK5, GRM1 | SMN1; SMN2 1712/4885ALDH1A1 4175/4885NPC1 1287/4885 |
| US-20090131454-A1 | New compounds 067 | UGT2B7, UGT1A7, CYP3A7 | SMN1; SMN2 3071/4885ALDH1A1 1808/4885NPC1 16/4885 |
| US-20080125436-A1 | 4-(5-{(1R)-1-[5-(3-Chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,- 4-triazol-3-yl)-1-methylpyridin-2(1H)-one; transient lower esophageal sphincter relaxations; gastroesophageal reflux disease; pain; anxiety; irritable bowel syndrome; metabotropic glutamate receptor inhibitors; peripherally acting | GLRA1, GRM1, GRM5 | SMN1; SMN2 1286/4885ALDH1A1 500/4885NPC1 3903/4885 |
| US-20110306768-A1 | PROCESSES FOR THE MANUFACTURE OF 3--PYRIDINE, 4-METHYL-3-METHYLTHIO-5-(3-PYRIDYL)-L,2,4-TRIAZOLE, AND (1R)-1-[2-(3-METHYLPHENYL)-2H-TETRAZOL-5-YL]ETHANOL | ADH1A, ADH5, ADH1C | SMN1; SMN2 2439/4885ALDH1A1 32/4885NPC1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.